| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
|
| [2] |
Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis[J]. Cancer Biol Med, 2018, 15(2):124-136.
|
| [3] |
Hu Q, Zhou Y, Ying K, et al. IGFBP, a novel target of lung cancer?[J]. Clin Chim Acta, 2017, 466:172-177.
|
| [4] |
Kubasiak JC, Seder CW, Pithadia R, et al. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2015, 149(3):727-734, e1-3.
|
| [5] |
Huynh H, Chow PK, Ooi LL, et al. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation[J]. Cell Growth Differ, 2002, 13(3):115-122.
|
| [6] |
Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-102.
|
| [7] |
Sharma J, Gray KP, Evan C, et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival[J]. Prostate, 2014, 74(3):225-234.
|
| [8] |
Dai B, Ruan B, Wu J, et al. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma[J]. Int J Clin Exp Pathol, 2014, 7(9):5645-5654.
|
| [9] |
Yao X, Sun S, Zhou X, et al. IGF-binding protein 2 is a candidate target of therapeutic potential in cancer[J]. Tumour Biol, 2016, 37(2):1451-1459.
|
| [10] |
Wang J, Hu ZG, Li D, et al. Gene expression and prognosis of insulinlike growth factorbinding protein family members in nonsmall cell lung cancer[J]. Oncol Rep, 2019, 42(5):1981-1995.
|
| [11] |
Wang H, Wang H, Li K, et al. IGFBP-3 is the key target of sanguinarine in promoting apoptosis in hepatocellular carcinoma[J]. Cancer Manag Res, 2020(12):1007-1015.
|
| [12] |
Mosig RA, Lobl M, Senturk E, et al. IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer[J].J Ovarian Res, 2012, 5(1):3.
|
| [13] |
Ueno K, Hirata H, Majid S, et al. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma[J]. Int J Cancer, 2011, 129(10):2360-2369.
|
| [14] |
Lee YY, Mok MT, Kang W, et al. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis[J]. Nucleic Acids Res, 2018, 46(17):8832-8847.
|
| [15] |
Butt AJ, Dickson KA, McDougall F, et al. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo[J]. J Biol Chem, 2003, 278(32):29676-29685.
|